comparemela.com

Latest Breaking News On - Jonathan aschoff - Page 2 : comparemela.com

Panbela Therapeutics, Inc (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript

Operator: Greetings. Welcome to Panbela Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

United statesJennifer simpsonJosh korsenJonathan aschoffJoe pantginisEflornithine pediatric neuroblastoma programAmerican society of hematologyStock market exchangeMoffitt cancer centerUniversity of texas md anderson cancer centerPanbela therapeutics incNational cancer instituteDiabetes research foundationIndiana university school of medicineOncology groupCollege education

Moleculin Biotech, Inc (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript

Operator: Greetings, welcome to the Moleculin Biotech 2023 Year-End Conference Call and Webcast. [Operator Instructions] Please note, that this conference is being recorded.

United statesJohn paul waymackBarry whiteJonathan fosterPaul waymackWalter klempJenene thomasJonathan aschoffVernon bernardinoMoleculin biotech incMetabasis therapeutics incCollege educationExchange commissionMoleculin biotechCall transcript marchEnd conference call

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Shaun bagaiJonathan aschoffSecurities exchangeSenior research analyst at rothExchange commissionRitz carltonRenovorx incStrategic communicationsCompany nasdaqChief executive officerDana pointSenior research analystTrans arterial micro perfusionOpportunities conferenceDrug evaluationSecurities act

FWBI keeps Buy rating at Roth - Cantech Letter

Following news of an acquisition, Roth MKM analyst Jonathan Aschoff remains bullish on First Wave BioPharma

Chaitan khoslaJonathan aschoffJames sapirsteinJack syageStanford universityFirst wave biopharmaFirst wave biopharma stock quoteFirst waveProfessor chaitan khosla

Buy these stocks for a potentially choppy 2024, Roth MKM says

Roth MKM believes 2024 could prove to be a volatile year for stocks. Here are some of the firm's top picks.

United statesCellectar biosciencesJoseph reagorRohit kulkarniSam adamsPhilip shenJonathan aschoffFederal reserveDrug administrationLithium electricPiedmont lithiumBoston beerAnalyst bill kirkInvestment strategyBreaking news businessBiotech and pharmaceuticals

vimarsana © 2020. All Rights Reserved.